Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Q-Cells Transplantation in Transverse Myelitis
NCT03887273Phase 2Recruiting
- Sponsor
- Q Therapeutics
- Start
- Sep 2022
- Primary completion
- Jul 2027
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 2, open-label trial of Q-Cells in transverse myelitis (TM) (3 arms), sponsored by Q Therapeutics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 9 months. Started Sep 2022; status: recruiting.
02
Drugs
Q-Cells
03
Conditions
transverse myelitis (TM)
Beyond the preview
Go deeper on NCT03887273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03887273.